EC offers Grants to strengthen Ethics and Regulatory Capacity

Deadline: 29-Jun-23

The European Commission (EC) is offering grants to strengthen ethics and regulatory capacity in SSA countries under the Horizon Europe Framework Programme (HORIZON).

Scope

• The aim of this call is to improve the functionality, recognition and performance of NECs and NRAs for carrying out clinical trials in SSA countries.
• Despite ongoing efforts by different partners and agencies, ethics, and regulatory oversight in SSA countries requires prioritisation and ownership by these countries to ensure sustained strengthening with a long-term perspective. There is a need to better understand the challenges that these countries are facing. They include the varied levels of clinical trial activity, with no health research legislation in some of them; as well as the need of better quality control, certification and accreditation of ethics and regulatory bodies, adherence to common international standards and open data access. Coherent linkages between ethics and regulatory functions are needed, as well as linkages with clinical trial registration and more systematic research reviews. Furthermore, better systems and technologies, including more external expertise and digitalisation for processing research application review and handling of documentation and data, are required.
• Several initiatives have already established capacity development tools and structures that add value to the capacity development efforts of ethics and regulatory agencies in SSA and should be taken into consideration.
• The projects funded under this call will support the SSA countries to establish and/or develop own robust capacities for ethics review and national medicines regulatory systems. This also includes support towards national and international collaboration in compliance with established international standards. This scheme targets proposals with active involvement of NECs and/or NRAs from SSA countries, and in particular with those countries with the highest infectious disease burden.
• Proposals should address several of the following activities:
  • Improvement of the efficiency of the functioning of NECs and NRAs through the introduction of innovative systems, reliance practices and/or technologies that would facilitate the various functions of these bodies with better quality outputs and improved timelines;
  • Development of national health research legislation;
  • Promotion of quality control systems and processes for NECs and NRAs, as well as certification and accreditation of the various bodies, as well as adherence to international standards;
  • Promotion of international cooperation in ethics and regulatory activities through transfer of promising and successful innovative systems and/or technologies from other regions in Africa or other continents, fostering national and regional collaboration among these bodies;
  • Creation of linkages between ethics and regulatory functions with other important structures, such as clinical trial registries, whilst simultaneously enforcing the sharing of data in compliance with global requirements;
  • Promotion of the adoption and update of AVAREF, WHO and other international standards and best practices, by countries, groups of countries, or regional harmonisation initiatives;
  • Support already established training centres to provide both innovative training, and mentorship to NECs and NRAs.
  • Development or scale-up of innovative systems and technologies that support ethics and regulatory functions, training, networking and promotion of good practices and evidence-based adoption of accreditation models from relevant internationally endorsed/peer-reviewed documented sources.
• Proposals should clearly indicate the mismatch between the country disease burden, research activity and level of ethical review and regulatory oversight that justify the need for support in these areas.
• Linkages of the proposal to relevant on-going initiatives and regional bodies is encouraged and should be demonstrated. Plans to foster bi-lateral links between the European Medicines Agency (EMA) and the national ethics and regulatory authorities in the SSA countries of the participants are encouraged.
• Each proposal should have at least two new technical staff members recruited to the NEC/NRA team to be trained and integrated in the new functions proposed in the action. The new staff members should have a well-defined function and objectives in the participating NEC and NRA with a systems approach. The new staff members should stay in the team for at least two years and participate in relevant networking and international events.
• Particular attention should also be paid in the proposal for ensuring complementarity and coherence with other activities supported by the European Union and EU Member States in the countries involved. This concerns for example the EDCTP Regional Networks of Excellence and the Team Europe initiative on Manufacturing and Access to Vaccines, Medicines, and Health Technologies (MAV+) in Africa or other health Team Europe initiatives of the Global Gateway investment package.
• To strengthen the clinical research capacity in the SSA regions with the highest disease burden, the quality of the transfer of knowledge should be taken particularly into account when evaluating the criterion ‘impact’.
• Proposals should provide details on the steps to be taken to ensure gender balance and contribute to have representation from French speaking and Portuguese speaking SSA countries in the project team.

Funding Information

• The check will normally be done for the coordinator if the requested grant amount is equal to or greater than EUR 500 000, except for:
  • public bodies (entities established as a public body under national law, including local, regional or national authorities) or international organisations; and
  • cases where the individual requested grant amount is not more than EUR 60 000 (low value grant).

Expected Outcome

Projects funded under this Call for Proposals should contribute to the following outcomes:

• Stronger functionality, recognition, and performance of National Ethics Committees (NECs) and National Regulatory Agencies (NRAs) working in sub-Saharan Africa (SSA);
• Clinical trials authorised in these areas meet the appropriate standards;
• Improved efficiency regarding the process of clinical trial protocol authorisation for the development of new or improved health technologies;
• Improved efficiency of the NRAs concerning clinical trials oversight with alignment to continental initiatives of African Medicine Agency (AMA) and African Medicines Regulatory Harmonisation (AMRH);
• Better equipped health research systems to integrate new or improved health technologies;
• Sustainable health research strategies for both NECs and NRAs;
• Adoption of standardised training of both ethics committees and regulatory boards available in SSA through EDCTP partners;
• Generation of principles towards harmonised oversight for certification of clinical trial ethics and regulatory bodies in SSA countries;
• Creation of sustainable links and collaboration between NECs and NRAs and other important structures, such as clinical trial registries, research integrity offices and data access committees;
• Establishment of systematic reviews and data sharing in compliance with global requirements;
• Implementation of digital technologies to facilitate ethical and/or regulatory review processes.

Expected Impact

Activities funded under the 2023 calls for proposals should contribute to:

• Achieve SDG3 ‘Ensure healthy lives and promote well-being for all at all ages’ in sub-Saharan African countries;
• Enable the implementation of the short and medium term actions foreseen by the AU EU Innovation Agenda (expected to be adopted in June 2023) in the area of Public Health
• Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;
• Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;
• Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;
• Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;
• Strengthen health systems to ensure uptake of effective health technologies and innovations;
• Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.
• Improve opportunities for training of researchers and healthcare professionals in sub-Saharan Africa.

Eligibility Criteria

• To become a beneficiary, legal entities must be eligible for funding.
• To be eligible for funding, applicants must be established in one of the following countries:
  • the Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.
  • the Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR).
  • countries associated to Horizon Europe; Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine.
• Specific cases
  • Affiliated entities — Affiliated entities are eligible for funding if they are established in one of the countries listed above, or in a country identified in the specific call conditions.
  • Associated partners — Entities not eligible for funding (and therefore not able to participate as beneficiaries) may participate as associated partners, unless specified otherwise in the specific call conditions.
  • EU bodies — Legal entities created under EU law may also be eligible to receive funding, unless their basic act states otherwise.
  • International organisations — International European research organisations are eligible to receive funding. Unless their participation is considered essential for implementing the action by the granting authority, other international organisations are not eligible to receive funding.

For more information, visit European Commission (EC).